← Back to Clinical Trials
Recruiting NCT06783855

NCT06783855 Outcomes of Uretheroileal Suspension Technique During Open Radical Cystectomy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06783855
Status Recruiting
Phase
Sponsor Sohag University
Condition Radical Cystectomy
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2025-01-01
Primary Completion 2026-01-01

Trial Parameters

Condition Radical Cystectomy
Sponsor Sohag University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 60
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2025-01-01
Completion 2026-01-01
Interventions
suspension uretheroileal techniqueconventional radical cystectomy and ileal neobladder

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The suspension technique is reported as the puboprostatic ligaments that attach the prostate to the symphysis pubis. After the ligating the complex, including both the dorsal vein complex and the puboprostatic ligaments, this complex was sharply divided anteriorly from the prostate with a safe distance (1-2 mm), and the urethra is defined and divided. After removing the prostate, the ileal pouch is reconstructed by completely everting the mucosa and sutured outward with a running 4-0 absorbable suture around the edge. The neck of the neobladder was narrowed to ≈1 cm, for convenient passage of a 20 F catheter. Anastomotic sutures of 3-0 absorbable polyglactin were placed at the 1, 3, 5, 6, 7, 9, 11 and 12 o'clock positions

Eligibility Criteria

Inclusion Criteria: * Patient age \>18 years. * Muscle-invasive bladder carcinoma (MIBC). * Non-muscle-invasive bladder carcinoma (NMIBC) fulfilling the following criteria: 1. \- (recurrent disease that is unresponsive to other treatments 2. \- high-grade tumors (T1, carcinoma in situ) refractory to intravesical therapy 3. -Multifocal or recurrent high-grade tumors despite intravesical therapy and the tumor progression from NMIBC to MIBC). Exclusion Criteria: * NMIBC or benign disease. * Severe hepatic renal dysfunction. * Urethral involvement with bladder carcinoma. * Poor overall health status. * Severe renal dysfunction.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology